News
7h
Zacks.com on MSNIs Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...
11h
Zacks.com on MSNIs Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...
Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...
With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...
Eli Lilly and Company (NYSE: LLY) faced a sharp setback on Monday as HSBC issued a rare double downgrade, slashing its rating ...
Mounjaro, the new weight loss drug, is gaining popularity in India for its rapid results. Patients report better appetite control, blood sugar management, and significant weight loss.
Approved by India’s apex drug regulatory body, the weight-loss drug is a once-weekly injection priced at Rs 4,375 for a 5 mg ...
7h
Stocktwits on MSNEli Lilly Stock Gets A Double Downgrade And Price Target Cut By HSBC Over Valuation, Competition ConcernsHSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...
The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...
Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.
Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results